Next Article in Journal
Rare Monogenic Diseases: Molecular Pathophysiology and Novel Therapies
Next Article in Special Issue
Biological Role of the Intercellular Transfer of Glycosylphosphatidylinositol-Anchored Proteins: Stimulation of Lipid and Glycogen Synthesis
Previous Article in Journal
The Role of Heparan Sulfate in CCL26-Induced Eosinophil Chemotaxis
Previous Article in Special Issue
The First Homologous Expression System for the β-Lytic Protease of Lysobacter capsici VKM B-2533T, a Promising Antimicrobial Agent
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 12
10.3390/ijms23126515
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Serotonin Receptors as Therapeutic Targets for Autism Spectrum Disorder Treatment

by
Ansoo Lee
1,2,
Hyunah Choo
1,2,* and
Byungsun Jeon
1,2,*
1
Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Korea
2
Division of Bio-Medical Science & Technology, KIST School, University of Science and Technology, Seoul 02792, Korea
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2022, 23(12), 6515; https://doi.org/10.3390/ijms23126515
Submission received: 18 May 2022 / Revised: 8 June 2022 / Accepted: 8 June 2022 / Published: 10 June 2022
(This article belongs to the Collection G Protein-Coupled Receptors and Their Kinases in Cell Biology and Disease)
Review Reports Versions Notes

Abstract

:
Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by repetitive and stereotyped behaviors as well as difficulties with social interaction and communication. According to reports for prevalence rates of ASD, approximately 1~2% of children worldwide have been diagnosed with ASD. Although there are a couple of FDA (Food and Drug Administration)—approved drugs for ASD treatment such as aripiprazole and risperidone, they are efficient for alleviating aggression, hyperactivity, and self-injury but not the core symptoms. Serotonin (5-hydroxytryptamine, 5-HT) as a neurotransmitter plays a crucial role in the early neurodevelopmental stage. In particular, 5-HT has been known to regulate a variety of neurobiological processes including neurite outgrowth, dendritic spine morphology, shaping neuronal circuits, synaptic transmission, and synaptic plasticity. Given the roles of serotonergic systems, the 5-HT receptors (5-HTRs) become emerging as potential therapeutic targets in the ASD. In this review, we will focus on the recent development of small molecule modulators of 5-HTRs as therapeutic targets for the ASD treatment.

1. Introduction

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with heterogeneous etiology. Core symptoms of ASD include impaired social interactions, stereotyped repetitive behaviors, and restricted interests [1]. ASD is considered to be caused by genetic and environmental factors including maternal/paternal age, fetal environment, nutrition, and toxic exposures [2,3]. Since epidemiological investigation of ASD started in the mid-1960s [4,5], many countries have reported prevalence rates of ASD annually. The prevalence rates of ASD are notably becoming higher each year with present rates of approximately 1~2% worldwide, although there are a variety of reasons for this significant increase in the prevalence such as improved ASD diagnostic techniques and the rising awareness [6,7,8,9]. Given the growing concerns, development of treatments for ASD thus becomes a priority in recent public health issues. There are only a couple of FDA-approved drugs for ASD such as aripiprazole and risperidone [10,11,12,13,14]. They are certainly effective for alleviating the symptoms including aggression, hyperactivity and self-injury but not the ASD core symptoms as mentioned above. Effective therapeutics for the core symptoms thus remain underdeveloped to date due to lack of understanding etiology and pathological mechanisms for ASD [15].
Over the past decades, human clinical studies have been accumulated and several animal models for treatment of core symptoms in ASD have been developed [16,17]. Based on the development of these techniques, several potential mechanisms such as synaptic dysfunction (including excitatory/inhibitory imbalance in brain neural circuits and dendritic spine abnormalities) [18,19,20], neuroinflammation [21,22], and central neurotransmission systems [23,24,25] have been identified as therapeutic targets. Selective modulators of mGlu, NMDA, GABA receptors, and GSK-3β signaling pathway are known to regulate excitatory/inhibitory ratio, resulting in enhancement of neuroplasticity [18,19,20]. mTOR, ROCK kinases, and IGF1 system have been widely investigated to correct the dendritic spine abnormalities, while Toll-like receptors, involved in neuroinflammation, have been studied to modulate synaptic functions [21,22]. Serotonin as a key neurotransmitter plays a crucial role in the early neurodevelopmental stage. A variety of studies proposed that disturbances in serotonergic system are described in several neurodevelopmental disorders including ASD [25].
In particular, hyperserotonemia during pregnancy has been suspected as a potential environmental factor in the prevalence of ASD [26,27]. Selective serotonin reuptake inhibitors (SSRIs) that have been prescribed for the alleviation of depression antagonize serotonin transporter (SERT) and lead the increase of serotonin level in brain. Due to the potential connectivity, many studies have been reported the effect of SSRIs on ASD [15,28,29]. In 2011, Croen and co-workers investigated the effects of prenatal exposure to SSRIs on ASD risk. According to their population-based study (298 case children with ASD and 1507 control children), they found a two-fold increased risk of ASD with SSRIs exposure during prenatal period [30]. While more studies support the association, the opposite results have also been reported. Hviid and colleagues conducted a large number of cohort study between the use of SSRIs during pregnancy and ASD diagnosis in the offspring in Danish population [31]. They could not claim a significant association between the SSRIs exposure during pregnancy and ASD in the offspring. Payet and colleagues studied the period effect of SSRI exposure with young male BALB/c mice, a phenotype that is relevant to ASD [32]. The authors investigated the effects of chronic and acute administration of fluoxetine, showing a decrease in social behavior in acute exposure while an increase in social behavior in chronic treatment. Moreover, they found that acute and chronic treatments differentially affected serotonergic neuronal populations in the dorsal raphe nucleus. In addition to the controversial outcomes, the effects of SSRIs on ASD are still debating, further studies are needed to clarify the association.
Serotonin (5-hydroxytryptamine, 5-HT), biosynthesized from the amino acid tryptophan, is mainly found in serotonergic neurons, enterochromaffin cells, and blood platelets. 5-HT is a crucial hormone and neurotransmitter that controls a number of neurobiological processes in the central nervous system (CNS). These processes are mediated by a group of serotonin receptors (5-HTRs), which are classified into seven subfamilies (5-HT1–7R). The 5-HTRs belong to a family of G protein-coupled receptors (GPCRs), except for 5-HT3R, which is a ligand-gated ion channel. 5-HT system plays a fundamental role in neurite outgrowth, dendritic spine morphology, shaping neuronal circuits, synaptic transmission, and synaptic plasticity. Given the roles of 5-HT, a variety of diseases such as depression, anxiety, schizophrenia, and neurodevelopmental disorders (e.g., ASD, fragile X syndrome, and Rett syndrome) have a close relation with regulation of 5-HT systems [33,34,35,36]. As therapeutic targets in numerous brain diseases, 5-HT has thus become a highly important class of biogenic amines. In this review, we will focus on recent studies on 5-HTR modulators as ASD therapeutics.

2. 5-HT1 Receptor (5-HT1R)

5-HT1Rs consist of the largest class of 5-HTR subtypes, namely, five subtypes such as 5-HT1AR, 5-HT1BR, 5-HT1DR, 5-HT1ER, and 5-HT1FR and distribute in the CNS including brain. Similar to other 5-HTRs, all of 5-HT1Rs show a nanomolar affinity for 5-HT. They couple to Gαi/Gα0 proteins to inhibit adenylyl cyclase and modulate subsequent signaling pathway and ionic effectors such as potassium or calcium channel [37]. Since they were discovered, numerous investigations with selective agonists and antagonists for 5-HT1Rs have been pursued and clear-cut evidence of the implication of them in anxiety behaviors, cognitive performance and neurobehavioral abnormality in animal study suggests that they could be potential therapeutic targets in psychopathological and neurodevelopmental diseases.
Khatri and co-workers studied the lasting effects of neonatal activation of 5-HT1AR and 5-HT1BR in a rat model [38]. Using day 8 to 21 postnatal rat pups, the authors investigated both agonist and antagonist effects for 5-HT1AR and 5-HT1BR with the administration of various ligands such as 8-hydroxy-2-(di-n-propylamino)-tetraline (8-OH DPAT, 5-HT1AR agonist) (Table 1), or CGS-12066B (5-HT1BR agonist)(Table 1), WAY-100635 (5-HT1AR antagonist) (Table 1), or GR-127935 (5-HT1BR antagonist) (Table 1) or citalopram, a well-known SSRI. Similar to the treatment of SSRI, the agonists show increased stereotypic activity and impaired social interactions similar to that observed in ASD. On the contrary, the selective antagonists alleviate the abnormal behaviors in the presence of SSRI. Their direct and indirect findings suggest that both receptors may have important roles in brain development even after birth.
Hollander and colleagues investigated the relationship between repetitive behavior and growth hormone with sumatriptan (Table 1), a known migraine treatment and a 5-HT1DR agonist [39]. The authors reported that administration of sumatriptan increases growth hormone level in blood, which ameliorates repetitive behavior in adult autistic patient. Though the research was conducted with only small number of men and failed to link the 5-HT level in blood, the discovery that 5-HTRs could be a therapeutic target for ASD is clinically significant.
De Boer and co-workers pursued behavioral studies with F15599 (Table 1) and F13714 (Table 1), 5-HT1AR agonists, specifically Gαi biased compounds, in male wild-type Groningen rats [40]. In addition to mitigating aggressive behavior, both agonists showed reduced social interaction and concomitant motor inactivity in a dose dependent manner. However, the authors claimed that the effect of agonists was fully abolished when WAY-100635, a 5-HT1AR antagonist, was pretreated. The results imply that 5-HT1AR-Gαi signaling pathway is especially mediated and that could be a worthy target for study.
Cosi and colleagues investigated profile of F17464 (Table 1), a partial 5-HT1AR agonist and human dopamine receptor subtype 3 agonist [41]. In addition to exhibiting good binding affinity (Ki = 0.16 nM for 5-HT1AR) and comparable activity to well-known drugs such as aripiprazole (Table 1), lurasidone (Table 1), and etc., lack of high binding affinity toward 5-HT2AR has attracted much attention as an antipsychotic drug candidate without side effects. The authors further reported that F17464 rescued impaired social interaction in valproate-treated rats, an animal model of autism [42]. Their findings suggest that 5-HT1AR plays an important role in social behavior.
An interesting study addressing the mechanism of action of psychostimulants such as amphetamine and cocaine on suppressed social interaction was reported by Achterberg and co-workers [43]. A thorough combinational study with various receptor antagonists, the authors revealed that amphetamine depends on alpha-2 noradrenergic receptor while cocaine involves in dopamine, noradrenaline, and 5-HTRs. Though further studies should be followed, the negative effects of psychostimulant drugs and their involvement in the serotonergic system may provide the glimpse of the etiology of ASD.
Mogha and colleagues studied the effects of 5-HT1AR on signaling cascade using the C57BL/6 mice model [44]. The authors found that 5-HT1AR agonists increased PSD95 expression, a postsynaptic marker of spine and synapse maturation, and boosted dendritic spine and synapse formation via the sequential activation of the mitogen-activated protein kinase isozymes Erk1/2 and protein kinase C (PKC) in hippocampal region. Moreover, they observed that the stimulation of PKC restored the PSD95 expression and synaptogenesis in 5-HT1AR knockout mice. Their findings clearly show the importance of 5-HT1AR in signaling cascade to regulate hippocampal sculpting and function and indicate that 5-HT1AR has a crucial role in brain development.
Lawson and co-workers examined the effect of 5-HT1BR agonist, RU24969 (Table 1), on the behavioral patterns in C57BL/6J mice [45]. The mice treated with RU24969 show reduced sociability and preference for social novelty in three chamber test. Moreover, the agonist decreases average rearing duration, which is a putative measurement of non-selective attention in mice. Deficit of the behavior is thought to be related to ASD. Taken together, the results indicate that the activation of 5-HT1BR induces ASD-like behavior in mice. Interestingly, the authors rescued the ASD-like behavior in mice with oxytocin, a hypothalamic neuropeptide. The findings suggest that oxytocin might restore the social deficits through a mechanistic pathway involving 5-HT1BR and that targeting 5-HT1BR is a worthwhile strategy to treat ASD.
King and colleagues researched that fetal exposure to SSRI not only increases the serotonin level but also modulates p11 expression and neurogenesis in mice [46]. p11 protein was recently considered a crucial component of 5-HT signaling pathway through the complex formation with 5-HT1B/1D receptors in adult [47]. The authors observed that p11 protein was detected in most of the fetal brain including thalamus, cortex, and hindbrain. Interestingly, they showed SSRI exposure in utero reduced p11 expression only in thalamus and decreased neurogenesis in hippocampal NE and galionic eminences, indicating that maternally administered SSRI could reach the fetal brain and modify p11 expression and neurogenesis. Although they failed to demonstrate the direct linking between p11 and 5-HT1B/1D receptors, their results suggest that both receptors might influence p11 expression, which is important for neuronal development.
Rather than rodents, primate could be applied as a model animal. Larke and co-workers sought to evaluate social behavior in pair-bonded male titi monkeys when 5-HT1AR activity was modified by 8-OH-DPAT (Table 1), a selective agonist [48]. Contrary to many results in rodents, they monitored and quantified that the agonist led to at least two-fold decrease in affiliative social behaviors directed toward the pair-mate. Moreover, they found that the agonist reduced plasma concentration of cortisol without altering peripheral oxytocin level, which is increased in rodent cases. In addition to studying the effects of 5-HT1AR on behavior, their results are interesting not only using a monogamous primate for the first time, but also indicating a 5-HT1AR agonist affects social behavior differently between rodents and primates.
Wu and colleagues investigated the effect of deep brain stimulation (DBS) method and the mechanism in autistic animal model [49]. DBS is an emerging therapeutic approach for Parkinson’s disease, depression, and other psychiatric diseases. By applying DBS method in infralimbic prefrontal cortex (ILPFC) of a valproate (VPA)-induced rat, the authors observed reduced behavioral abnormalities. The autistic behaviors were further improved with the combination of DBS and 8-OH-DPAT (Table 1), a 5-HT1AR agonist. Moreover, they reported that the expression level of glutamatergic and GABAergic neurons in PFC region was restored. They further confirmed that DBS treatment was unsuccessful in the presence of WAY100635 (Table 1), a 5-HT1AR antagonist. All of their results suggest that DBS treatment is effective via the 5-HT1AR system.
Witt and co-workers tried to validate the effectiveness of vortioxetine (Table 1), a multimodal antidepressant, acting as an agonist for 5-HT1AR and 5-HT1BR and an inhibitor for 5-HT transporter [50]. The authors used BTBR T+Itpr3tt/J mice that lack social interaction preference and exhibit restrictive-repetitive behaviors. They observed high dose of vortioxetine could effectively decrease marble burying behaviors, and enhance social interaction although the effect was transient. Two-fold difference of vortioxetine preference toward 5-HT1AR and 5-HT1BR and the observation of low serum oxytocin level might be the reason of transiently enhanced sociability. Their results indicate that small molecules, which balance the nature to 5-HT1AR and 5-HT1BR, can be potential candidates for ASD by suppressing restrictive-repetitive behaviors and rescuing sociability.
SERT gene variant study by Veenstra-VanderWeele and colleagues suggested that 5-HT levels were closely associated with ASD [24]. The authors used SERT Ala56 variant from the native mouse Slc6a4 locus, which exhibit normal growth and fertility but show enhanced CNS 5-HT clearance, increased 5-HTR sensitivity, and hyperserotonemia. Significantly, enhanced phosphorylation of p38 MAPK-dependent transporter and CNS 5-HT clearance in SERT Ala56 model appear to decrease synaptic 5-HT availability and thus increase a compensatory 5-HTR sensitivity. They further validated the effect with small molecules, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and 8-OH-DPAT, 5-HT2A/2C and 5-HT1A/7 receptor agonist, respectively. Moreover, in their model, the authors observed a decrease in social interaction and an increase in repetitive behaviors, a stereotypy of ASD.
Table
Table 1. 5-HT1R-targeted pharmacological agents which have potential effects on ASD treatment.
Table 1. 5-HT1R-targeted pharmacological agents which have potential effects on ASD treatment.
NamesStructuresTargetsEffects
8-OH-DPAT [24,38,44,48,49] Ijms 23 06515 i0015-HT1AR/5-HT7R agonistIncreased stereotypic behavior and impaired social interaction via the disruption of sensory processing; enhanced dendritic spine and synapse formation; rescued sociability deficits, anxiety and hyperactivity with DBS treatment
CGS-12066B [38] Ijms 23 06515 i0025-HT1BR agonistIncreased stereotypic behavior and impaired social interaction via the disruption of sensory processing
WAY-100635 [38] Ijms 23 06515 i0035-HT1AR antagonistSlightly alleviate stereotypic behavior in the presence of SSRI
GR-127935 [38] Ijms 23 06515 i0045-HT1BR antagonistSlightly alleviate stereotypic behavior in the presence of SSRI
Sumatriptan [39] Ijms 23 06515 i0055-HT1DR agonistReduce repetitive behavior via an increase of growth hormone
F15599 [40] Ijms 23 06515 i0065-HT1AR agonistAnti-aggressive effects and reduction of social interaction and an increase of motor inactivity
F13714 [40] Ijms 23 06515 i0075-HT1AR agonistAnti-aggressive effects and reduction of social interaction and an increase of motor inactivity
F17464 [41] Ijms 23 06515 i0085-HT1AR partial agonist/D3R antagonistIncreases dopamine release, rescues impaired social interaction
Aripiprazole [10,11,12,13,14] Ijms 23 06515 i009Affinity to 5-HT1AR/5-HT2AR/5-HT2BR/5-HT7R; D2R/D3R/D4RIrritability amelioration
Lurasidone [10,11,12,13,14] Ijms 23 06515 i0105-HT2AR/5-HT7/D2R antagonist; 5-HT1AR partial agonistIrritability and aggressive behavior amelioration
RU24969 [45] Ijms 23 06515 i0115-HT1BR agonistInduce autism-like behavior including a decrease in social interaction
Vortioxetine [50] Ijms 23 06515 i0125-HT1AR/5-HT1BR agonist/inhibitor for SERTTransiently suppress repetitive behavior and enhance social interaction

3. 5-HT2 Receptor (5-HT2R)

5-HT2 receptor is a member of the rhodopsin family of GPCRs, which are coupled with Gq/G11, and consists of three subtypes, 5-HT2AR, 5-HT2BR, and 5-HT2CR. 5-HT2AR and 5-HT2CR are widely distributed in the CNS, while 5-HT2BR shows a restricted expression pattern in the CNS. 5-HT2Rs have been known to regulate a variety of signaling pathways in neurons including phospholipase C (PLC), phospholipase A2 (PLA2), and extracellular signal-regulated kinases (ERK) pathway [51,52]. The regulation of 5-HT2Rs is involved in the neuronal functions and activities, which are related with social behavior, cognitive function, anxiety, and the other neurodevelopmental disorders.
Molecular imaging studies of serotonin in ASD become crucial evidence of serotonergic abnormalities in the CNS of autistic individuals [53]. Initially, Chugani et al. used α-[11C]-methyl-L-tryptophan as a positron emission tomography (PET) tracer for serotonin synthesis [54]. This study discovered asymmetric serotonin synthesis in frontal cortex, thalamus, and dentate nucleus of the cerebellum in autistic children. In most cases, decreased serotonin synthesis was observed in frontal cortex and thalamus, whereas increased serotonin synthesis was observed in dentate nucleus. Moreover, the same research group found that the enhancement of capacity of brain serotonin synthesis during childhood is disrupted in autistic children [55]. In particular, Goldberg et al. performed a PET study using [18F]setoperone to image 5-HT2Rs in parents of autistic children [56]. This study demonstrated that cortical 5-HT2 binding potentials were notably lower in the parents compared with controls. Beversdorf et al. also used [18F]setoperone as the PET tracer to visualize 5-HT2Rs in adults with ASD [57]. The authors observed that thalamic [18F]setoperone binds less to 5-HT2Rs in autistic individuals than controls.
In addition, recent studies applying polymorphisms in the serotonin 2A receptor gene (HTR2A) in patients proved that 5-HT2R is genetically associated with ASD. Gadow et al. let parents of autistic children rate depressive symptoms of their children and then investigated association between the scores and functional single nucleotide polymorphisms in the HTR2As, rs6311 and rs6314. The authors found that rs6311 may control the severity of depression in autistic children [58]. Smith et al. also supported that the rs6311 is associated with ASD based on the mRNA expression analysis and family-based clinical studies with ASD patients [59]. Given the molecular imaging and genetic evidence between serotonergic systems and ASD, 5-HT2Rs have been considered as important targets for treating ASD.
Risperidone and aripiprazole are only approved by the FDA for use in ASD to date. These drugs have been classified as atypical antipsychotics and used to treat irritability, self-injury, as well as aggression but not the core symptoms of ASD. Other atypical antipsychotics such as olanzapine, paliperidone, and cariprazine have been used or tested for treatment in ASD. Atypical antipsychotics generally show antagonist or partial agonist activity on both dopamine- and serotonin-receptors including 5-HT2Rs. Olanzapine (Table 2) acts as an antagonist at 5-HT2A/2C and D2 dopamine receptors. When olanzapine was treated in autistic individuals, significant improvements in stereotyped behavior, social deficits, hyperactivity, irritability and aggression were observed in several case studies. However, it is known to cause various adverse effects [60]. Stigler et al. performed open-label study of paliperidone (9-hydroxyrisperidone) (Table 2), a 5-HT2AR antagonist, in 25 autistic individuals. Among the 25 subjects, 84% showed improvement based on a Clinical Global Impressions-Improvement (CGI-I) Scale. This study suggested that paliperidone treatment is significantly efficacious for irritability in autistic patients [61]. Cariprazine (Table 2), approved for treatment of schizophrenia and bipolar disorder, is a D3R, D2R, and 5-HT1AR partial agonist. The compound also acts as an antagonist at 5-HT2AR and 5-HT2BR. Román et al. very recently evaluated the cariprazine as treatment in autistic-like rats induced by the prenatal VPA exposure. The authors found that cariprazine is more efficient in the social play than risperidone and aripiprazole. In addition, cariprazine showed similar efficacy on behavioral tests to risperidone and aripiprazole (Table 1) [62]. Since atypical antipsychotics act at multiple receptor sites including dopamine- and serotonin-receptors as mentioned earlier, the drugs are able to cause various side effects such as weight gain, fatigue, gastrointestinal symptoms, hyperprolactinemia, sedation, and extrapyramidal symptoms. Taken together, more targeted approach using selective ligands is highly required to develop treatment minimizing adverse effects in ASD.
The selective 5-HT2AR antagonist M100907 (Table 2) has been applied to a potential therapeutic for ASD. Amodeo et al. investigated effects of risperidone and M100907 on the probabilistic reversal learning in autism mouse models, BTBR T+tf/J and C57BL/6J (B6). Both of the drugs enhanced reversal learning in BTBR mice, whereas higher dose of risperidone in B6 mice impaired reversal learning [63]. Treatment of M100907 was also efficient for attenuating repetitive grooming behavior in the BTBR mice, although meaningful effect on locomotor activity was not observed [64]. The same research group demonstrated that microinfusion of M100907 into the dorsomedial striatum in the BTBR mouse strain reduced reversal learning impairment and grooming behavior [65]. Panzini et al. studied the effect of M100907 in 16p11.2 deletion model mouse (Del mouse). Copy number variations of the region 16p11.2 are associated with ~1% of autism-related disorders. M100907 returned to normal level of active coping and improved the gradual shift to passive coping in Del mice [66].
In addition, Baker et al. investigated effects of another 5-HT2AR antagonist, ketanserin (Table 2), on strategy-switching in Long-Evans rats. Administration of ketanserin improved behavioral switching between visual cue and response strategy [67]. Given the beneficial effects of 5-HT2AR antagonists in various autism mouse models, the selective 5-HT2AR antagonists become promising potential therapeutics for ASD.
One research investigated how activation of 5-HT2AR and 5-HT2CR affects behavioral flexibility in an autism mouse model, B6 mouse. DOI (a 5-HT2A/2C receptor agonist)(Table 2), 25CN-NBOH (a selective 5-HT2AR agonist) (Table 2), and SER-082 (a 5-HT2CR antagonist)(Table 2) were used to demonstrate that 5-HT2AR agonism impairs probabilistic reversal learning. Treatment of B6 male mice with DOI alone did not impair behavioral flexibility, while cases of combination between SER-082 and DOI showed the impairment. Moreover, administration of 25CN-NBOH elevated the number of trials to criterion on a reversal learning task. This study thus proposed that 5-HT2AR activation causes impairments on probabilistic reversal learning while co-activation of 5-HT2CR is probably able to prevent the impairments [68]. Previous studies on association between 5-HT2AR and 5-HT2CR supported that these two receptors bring opposing effects on behavioral flexibility [69,70].
Some reports showed the contrary results to what 5-HT2AR activation produces on social behavior in autism mouse models. Knöpfel et al. investigated effects of psilocybin (Table 2), which is known as a serotonergic psychedelic drug and a 5-HT2AR agonist, on social behavior in B6 mouse model exposed prenatally to VPA. To exclude acute psychedelic effects, the authors performed sociability and social memory behavioral tests after 24 h following administration of psilocybin. The results showed that psilocybin ameliorate the social behavioral abnormalities in the autism model mice [71]. In addition, treatment of 5-HT2CR antagonist SB242084 (Table 2) in the ASD risk gene Pten haploinsufficient mice rescued the social behavior deficits [72], whereas one research reported that SB242084 did not enhance strategy switching [67].
Table
Table 2. 5-HT2 receptors-targeted pharmacological agents which have potential effects on ASD treatment.
Table 2. 5-HT2 receptors-targeted pharmacological agents which have potential effects on ASD treatment.
NamesStructuresTargetsEffects
Olanzapine [60] Ijms 23 06515 i0135-HT2AR/5-HT2CR/D2R antagonistIrritability amelioration
Paliperidone [61] Ijms 23 06515 i0145-HT2AR antagonistSignificant improvement in irritability
Cariprazine [62] Ijms 23 06515 i0155-HT2AR/5-HT2BR antagonist, 5-HT1AR/D2R/D3R partial agonistAlleviation of ASD core behavioral deficits
M100907 [63,64,65,66] Ijms 23 06515 i0165-HT2AR antagonistImprovement of probabilistic reversal learning; reduced repetitive behaviors
Ketanserin [67] Ijms 23 06515 i0175-HT2AR/H1R antagonistEnhanced strategy-switching between a visual cue and response strategy
25CN-NBOH [68] Ijms 23 06515 i0185-HT2AR agonistImpairment of probabilistic reversal learning
DOI and SER-082 [68] Ijms 23 06515 i019DOI: 5-HT2AR/5-HT2CR agonist;
SER-082: 5-HT2BR/5-HT2CR antagonist		DOI alone did not impair reversal learning;
co-treatment of DOI with SER-082 impair reversal learning
Psilocybin [71] Ijms 23 06515 i0205-HT2AR agonistRescued the social behavioral abnormalities
SB242084 [67,72] Ijms 23 06515 i0215-HT2CR antagonistRescued social behavior deficits

4. 5-HT6 Receptor (5-HT6R)

5-HT6R is one of the latest discovered serotonin receptors and mainly localized in the striatum, cerebral cortex, as well as hippocampus [73,74,75,76]. These brain regions play a critical role in working memory, learning, and cognitive flexibility related with neurodevelopmental disorders including ASD [77,78]. Gs-adenyl cyclase activity is stimulated by 5-HT6R leading to cyclic adenosine monophosphate (cAMP) release [79]. 5-HT6 receptor also interacts with the tyrosine kinase Fyn that regulates cell proliferation, survival, and death [80]. Moreover, a variety of signaling pathways such as the ERK1/2 pathway, the Jun activation domain-binding protein 1 (Jab1) pathway, the microtubule-associated protein (Map1b) pathway, and the mTOR pathway are involved in 5-HT6R signaling [81,82,83]. In particular, the mTOR pathway is known to be closely related with neurodevelopmental mechanisms [83]. Furthermore, 5-HT6R signaling pathways regulate other neurotransmitter systems such as cholinergic, glutamatergic, and dopaminergic systems, which may be linked with cognitive effects and mood regulation [84,85,86]. Given the roles of 5-HT6R in neurotransmitter systems, 5-HT6R has recently emerged as an interesting target for various brain disorders [87,88].
Ragozzino et al. demonstrated that PRX-07034 (Table 3), having an aryl piperazine core, is a highly potent and selective 5-HT6R antagonist compared to other GPCRs, ion channels, and transporters including other 5-HTRs [89]. PRX-07034 alleviated cognitive flexibility impairments and enhanced working memory as well as strategy switching in male Long-Evans rats. 5-HT6R blockade may affect acetylcholine release in the frontal cortex and striatum or directly glutamate transmission. The results thus suggested that PRX-07034 is probably effective for individuals having working memory impairments such as in ASD and schizophrenia.
Administration of other aryl piperazine 5-HT6R antagonists showed similar effects with PRX-07034 such as enhanced cognitive functions and memory consolidation. Bécamel et al. found that treatment of adult mice, which are exposed to cannabis during adolescence, with SB-258585 (Table 3) plays a crucial role to control synaptic plasticity, excitatory/inhibitory balance, and intrinsic neuronal properties via 5-HT6R-operated mTOR signaling network. The authors suggested that 5-HT6R antagonists might be evaluated in ASD based on the evidence of close relationship between mTOR and ASD [90]. In addition, treatment of SB-271046 (Table 3) and SB-399885 (Table 3) reversed scopolamine-induced deficits in aged rats. These compounds also improved task acquisition and ameliorated spatial task deficits [91,92].
Amodeo et al. reported that 5-HT6R blockade attenuated core symptoms of ASD in very recent [93]. To prove the assumption, BTBR T+Itpr3tf/J and C58/J (C58) mouse strains, showing repetitive behaviors and social deficits, had been used. Treatment of BTBR mice with a selective 5-HT6R antagonist BGC20-761 (Table 3) attenuated repetitive grooming activity regardless of sex while treatment of C58 mice with BGC20-761 increased social sniff time in female. The authors explained that 5-HT6R blockade promotes acetylcholine release leading to attenuation in repetitive behaviors in BTBR mice. Moreover, Neumaier et al. supported that BGC20-761 enhanced memory consolidation and cognitive function in rodents having social recognition deficits induced by an acetylcholine antagonist scopolamine, although BGC20-761 was not effective to attenuate anxiety behaviors [94].
Interestingly, one research investigated that activation of 5-HT6R probably impairs working memory and behavioral flexibility. When a 5-HT6R agonist EMD386088 (Table 3) was administrated in B6 mice, impairments of probabilistic reversal learning performance and spontaneous alternation performance were observed [95]. Given the recent findings of selective 5-HT6R antagonists on ASD core symptoms, the development of highly selective 5-HT6R modulators is desired for ASD therapeutics.

5. 5-HT7 Receptor (5-HT7R)

5-HT7 receptor is the most recently discovered 5-HT receptor among 5-HTR subtypes, which is largely distributed in the various area of brain such as thalamus, hypothalamus, and cortex, and regulates brain development, synaptic transmission and plasticity, learning and memory [96]. Four isoforms of 5-HT7R have been reported, namely, 5-HT7aR, 5-HT7bR, 5-HT7cR, and 5-HT7dR, and among them, only 5-HT7cR is not detected in human [97]. Similar to other 5-HTR, 5-HT7R is coupled to Gs protein, resulting in an increase of cAMP via the activation of adenylyl cyclase (AC). It can also recruit G12 protein, one of Gα subunits, which interacts with various RhoGEFs, inducing the activation of Rho GTPases [98]. Although a single base polymorphism for 5-HT7R was detected, an analysis of transmission disequilibrium in autistic patients failed to provide any correlation of allele to autism [99]. However, even though the dysfunction of 5-HT7R has not been reported in ASD patients, the distribution of 5-HT7R in functional brain area and some evidence implicate their involvement, as discussed below.
Khodaverdi and co-workers reported that the administration of 5-HT7R agonist, LP211 (Table 4), for a week rescues all behavioral deficits in an autistic-like rat model induced by an anti-migraine medication, VPA [100]. The authors revealed that the 5-HT7R agonist also restored the impaired synaptic plasticity in hippocampal region. Their findings clearly suggest that the serotonergic system, 5-HT7R, could be a promising pharmacotherapy target for ASD.
Canal and colleagues studied an aminotetralin derivative, (+)-5-FPT (Table 4), which is motivated from AS-19 and 8-OH-DPAT (Table 1) [101]. The compound has high affinity for 5-HT7R and 5-HT1AR and works as a partial agonist. In vivo studies in three heterogeneous mouse models revealed that the compound not only reduced stereotypy of ASD but also increased social interaction without causing significant side effects. Moreover, the authors pursued thorough pharmacokinetic study and claimed that orally operative (+)-5-FPT appears to be a promising candidate for ASD treatment. The group re-evaluated pharmacokinetic values and further validated the effect of (+)-5-FPT in a genetic model, Fmr1 knockout, and wild-type mice [102]. In addition to providing anxiolytic-like effects, it significantly relieved repetitive behavior and enhanced social interaction both in wild-type and the transgenic mice. After developing the lead compound, (+)-5-FPT, [101] Perry et al. synthesized more derivatives and pursued 3D-QSAR and molecular docking studies to understand important structural requirements. The authors found that a steric appendage either at C5- or chiral C2-position enhances selectivity for 5-HT7R or 5-HT1AR, respectively [103].
Many groups have tried to develop small molecules with fancy core structure. Motivated from bioactive molecules, Kelemen et al. synthesized and performed preliminary SAR (structure-activity relationship) analysis with spiro-oxindole derivatives [104]. Many of the compounds exhibit high affinity and selectivity for 5-HT7R over other 5-HTR subtypes. By exploiting knowledge-based design strategy, Lacivita and colleagues synthesized a variety of long-chain arylpiperazine derivatives and displayed interesting activity profiles such as dual 5-HT7/5-HT1A receptor agonist properties and mixed 5-HT7/5-HT1A receptor agonist/5-HT2AR antagonist properties [105]. The authors claimed that the compounds are metabolically stable in vitro and especially exhibit druglike properties, therefore, they could be potential candidates for ASD treatments.
As many studies on the GPCR signaling pathway have progressed, it has been found that not only G proteins but non-G protein factors such as β-arrestin are signal inducers in the signaling pathway [106]. To understand the mechanism well, ligands with functional selectivity or signaling biased ligands have been actively developed. Our group also has pursued biased ligands for 5-HT7R to understand its mechanism in ASD. Kim et al. developed a series of tetrahydroazepine derivatives with arylpyrazolo moiety or arylisoxazolo moiety consideration of pyrazole-based molecules [107] such as agonists E55888 [108] and AS-19 [109] and antagonist JNJ18038638 [110]. Among them, 3-(4-chlorophenyl)-1,4,5,6,7,8-hexahydropyrazolo [3,4-d] azepane acts as the selective and β-arrestin biased ligand for 5-HT7R. Although thorough studies were not pursued, modeling comparison with AS-19 suggested that ionic interaction with Asp162 and π-alkyl interaction with Ile233 appear to be important for the β-arrestin signaling pathway. Lee et al. more focused on the biphenyl core structure with variety of amine scaffolds [111]. In contrast with E55888, a balanced agonist, 2-(6-chloro-2′-methoxy-[1,1′-biphenyl]3-yl)-N-ethylethan-1-amine (Table 4) shows G-protein biased activity without affecting β-arrestin signaling pathway. Interestingly, the compound increased the duration of self-grooming in Shank3 transgenic mice, a typical behavior in ASD. More recently, Kwag et al. discovered G-protein biased antagonists by modifying pyrazolyl-diazepanes and pyrazolyl-piperazines [112]. Among the compounds, 1-(3-(3-chlorophenyl)-1H-pyrazol-4-yl)-1,4-diazepane (Table 4) showed the best selectivity over any other 5-HTRs and binding affinity for 5-HT7R. The compound dramatically reduced self-grooming duration time in Shank3 transgenic mice to the level of wild type mice. To understand why the compound acts as a G-protein biased antagonist, we further pursued docking analysis. While our previous compound forms an interaction with Ile233, [107] the compound resides in a hydrophobic pocket having ionic interaction with Asp162 and no interaction with Ile233, implying that Ile233 might be a crucial residue for β-arrestin signaling pathway. Both results of G-protein biased compounds suggest that 5-HT7R is associated with ASD and 5-HT7R could be a potential therapeutic target for the treatment of ASD.
Table
Table 4. 5-HT7R-targeted pharmacological agents which have potential effects on ASD treatment.
Table 4. 5-HT7R-targeted pharmacological agents which have potential effects on ASD treatment.
NamesStructuresTargetsEffects
LP211 [100] Ijms 23 06515 i0285-HT7R agonistRescue all behavioral deficits, and restores hippocampal synaptic plasticity impairment
(+)-5-FPT [101,102] Ijms 23 06515 i0295-HT1AR/5-HT2CR/5-HT7R partial agonistReduction of stereotypic behavior, social activity increase; reduced the number of audiogenic seizures
2-(4-(4-(4’-methoxy-[1,1’-biphenyl]-2-yl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione [105] Ijms 23 06515 i030Dual 5-HT1AR/5-HT7R agonistMetabolically stable and have suitable CNS druglike properties
6-((R)-2-hydroxy-3-(4-(4’-methoxy-[1,1’-biphenyl]-2-yl)piperazin-1-yl)propoxy)-2-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one [105] Ijms 23 06515 i031Dual 5-HT1AR/5-HT7R agonistMetabolically stable and have suitable CNS druglike properties
7-(3-(4-(4’-methoxy-[1,1’-biphenyl]-2-yl)piperazin-1-yl)propoxy)-4-methyl-2H-chromen-2-one [105] Ijms 23 06515 i032Mixed 5-HT1AR/5-HT7R agonist; 5-HT2AR antagonistMetabolically stable and have suitable CNS druglike properties
3-(4-chlorophenyl)-1,4,5,6,7,8-hexahydropyrazolo[3,4-d] azepane [107] Ijms 23 06515 i0335-HT7R agonist
(β-arrestin partial agonist)		Increase in non-rapid eye movement (NREM) sleep duration and decrease in REM sleep duration
2-(6-chloro-2′-methoxy-[1,1′-biphenyl]3-yl)-N-ethylethan-1-amine [111] Ijms 23 06515 i0345-HT7R agonist
(G protein biased agonist)		Increase in the duration of self-grooming
1-(3-(3-chlorophenyl)-1H-pyrazol-4-yl)-1,4-diazepane [112] Ijms 23 06515 i0355-HT7R antagonist
(G protein biased antagonist)		Decrease in the duration time of self-grooming

6. Conclusions and Future Perspectives

Among seven subfamilies of 5-HTRs, 5-HT1R, 5-HT2R, 5-HT6R, and 5-HT7R have been intensively investigated as potential targets for ASD. This review provides recent studies in development of small molecule modulators of these 5-HTRs as ASD therapeutic agents. A variety of selective agonists and antagonists for 5-HT1Rs have been developed and evaluated in autistic patients and some animal models to date. In particular, administration of 5-HT1AR, 5-HT1BR, and 5-HT1DR modulators ameliorate repetitive behavior and enhance social interaction which are core symptoms of ASD. PET studies of serotonin in ASD and polymorphisms in the HTR2A gene demonstrated that 5-HT2 receptors are associated with ASD. Afterward, numerous 5-HT2R modulators have been evaluated as ASD therapeutics. 5-HT2AR and 5-HT2CR antagonists including some atypical antipsychotics showed improvement in core symptoms in ASD patients and mice model, although one contrary case was reported that psychedelic prodrug psilocybin having 5-HT2AR agonism rescued social behavior deficits. Highly selective 5-HT6R antagonists such as PRX-07034, SB-258585, SB-271046, SB-399885, BGC20-761 enhanced cognitive function and memory as well as reduced repetitive behavior. Treatment of 5-HT6R agonist EMD386088 impaired behavioral flexibility and working memory in autism model mice. 5-HT7R modulators are known to improve altered behaviors and affect neuronal morphology. Recent development of G-protein biased ligands of 5-HT7R led to alleviation of self-grooming in autism mice. 5-HT7R thus becomes a potential therapeutic target for neurodevelopmental disorders including ASD [113].
Development of effective medications for ASD is challenging due to the properties of ASD such as the wide heterogeneity of factors and symptoms, absence of biomarkers, as well as different treatment outcomes depending on the age of patients. Despite continuous efforts for advancing ASD treatments, there are still only two FDA-approved drugs (risperidone and aripiprazole). Since the first classification of 5-HTR subtypes in 1957 [114], their structures, pharmacology, functions, signaling pathways, and clinical relevance have been disclosed [115]. As herein reviewed, 5-HTRs have recently emerged as potential targets for ASD because direct or indirect findings suggest that modulation of 5-HTRs is closely associated with ASD. In addition, as the targeted approach, treatments of selective modulators of 5-HTRs have been demonstrated to be effective for alleviating core symptoms of ASD and reducing side effects. Taken together, we believe that the development of a number of highly selective ligands for 5-HTRs will probably provide new opportunities for the discovery of ASD cures.

Author Contributions

Conceptualization, B.J. and H.C.; writing—original draft preparation, A.L. and B.J.; supervision, B.J. and H.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research is supported by the Basic Science Research Program (NRF-2021R1A2C2006244 to H.C. and NRF-2022R1C1C1006143 to B.J.) funded by the National Research Foundation of Korea (NRF). And this work is additionally funded by Korea Institute of Science and Technology (KIST) Institutional Program (2E31512 and 2E31523).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

We are grateful to the National Research Foundation of Korea (NRF) and Korea Institute of Science and Technology (KIST) for funding this project.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

ASDautism spectrum disorder
FDAFood and Drug Administration
5-HTSerotonin, 5-hydroxytryptamine
5-HTR5-HT receptor
SSRIselective serotonin reuptake inhibitor
SERTserotonin transporter
CNScentral nervous system
5-HTnR5-HTn receptor
GPCRG protein-coupled receptor
8-OH-DPAT8-hydroxy-2-(di-n-propylamino)-tetraline
PKCprotein kinase C
DBSdeep brain stimulation
ILPFCinfralimbic prefrontal cortex
VPAvalproate, valporic acid
DOI1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
PLCphospholipase C
PLA2phospholipase A2
ERKextracellular signal-regulated kinases
PETpositron emission tomography
HTR2Aserotonin 2A receptor gene
CGI-IClinical Global Impressions-Improvement
cAMPcyclic adenosine monophosphate
Jab1Jun activation domain-binding protein 1
Map1bmicrotubule-associated protein
ACadenylyl cyclase
SARstructure-activity relationship

References

  1. Lord, C.; Brugha, T.S.; Charman, T.; Cusack, J.; Dumas, G.; Frazier, T.; Jones, E.J.H.; Jones, R.M.; Pickles, A.; State, M.W.; et al. Autism spectrum disorder. Nat. Rev. Dis. Primers 2020, 6, 5. [Google Scholar] [CrossRef] [PubMed]
  2. Bölte, S.; Girdler, S.; Marschik, P.B. The contribution of environmental exposure to the etiology of autism spectrum disorder. Cell. Mol. Life Sci. 2019, 76, 1275–1297. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Geschwind, D.H. Genetics of autism spectrum disorders. Trends. Cogn. Sci. 2011, 15, 409–416. [Google Scholar] [CrossRef] [Green Version]
  4. Lotter, V. Epidemiology of autistic conditions in young children: I. Prevalence. Soc. Psychiatry 1966, 1, 124–137. [Google Scholar] [CrossRef]
  5. Lotter, V. Epidemiology of autistic conditions in young children: II. Some characteristics of the parents and children. Soc. Psychiatry 1967, 4, 163–173. [Google Scholar] [CrossRef]
  6. Fombonne, E. The epidemiology of autism: A review. Psychol. Med. 1999, 29, 769–786. [Google Scholar] [CrossRef]
  7. Hyman, S.L.; Levy, S.E.; Myers, S.M. Identification, Evaluation, and Management of Children with Autism Spectrum Disorder. Pediatrics 2020, 145, e20193447. [Google Scholar] [CrossRef] [Green Version]
  8. Yoon, S.H.; Choi, J.; Lee, W.J.; Do, J.T. Genetic and Epigenetic Etiology Underlying Autism Spectrum Disorder. J. Clin. Med. 2020, 9, 966. [Google Scholar] [CrossRef] [Green Version]
  9. Levy, S.E.; Mandell, D.S.; Schultz, R.T. Autism. Lancet 2009, 374, 1627–1638. [Google Scholar] [CrossRef]
  10. Stigler, K.A.; Diener, J.T.; Kohn, A.E.; Li, L.; Erickson, C.A.; Posey, D.J.; McDougle, C.J. Aripiprazole in Pervasive Developmental Disorder Not Otherwise Specified and Asperger’s Disorder: A 14-Week, Prospective, Open-Label Study. J. Child Adolesc. Psychopharmacol. 2009, 19, 265–274. [Google Scholar] [CrossRef] [Green Version]
  11. Marcus, R.N.; Owen, R.; Kamen, L.; Manos, G.; McQuade, R.D.; Carson, W.H.; Aman, M.G. A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents with Irritability Associated with Autistic Disorder. J. Am. Acad. Child Adolesc. Psychiatry 2009, 48, 1110–1119. [Google Scholar] [CrossRef]
  12. Blankenship, K.; Erickson, C.A.; Stigler, K.A.; Posey, D.J.; McDougle, C.J. Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6–17 years. Pediatr. Health 2010, 4, 375–381. [Google Scholar] [CrossRef]
  13. Knight, J.A.; Smith, C.; Toohey, N.; Klein, M.T.; Teitler, M. Pharmacological Analysis of the Novel, Rapid, and Potent Inactivation of the Human 5-Hydroxytryptamine7 Receptor by Risperidone, 9-OH-Risperidone, and Other Inactivating Antagonists. Mol. Pharmacol. 2009, 75, 374–380. [Google Scholar] [CrossRef]
  14. Smith, C.; Toohey, N.; Knight, J.A.; Klein, M.T.; Teitler, M. Risperidone-Induced Inactivation and Clozapine-Induced Reactivation of Rat Cortical Astrocyte 5-Hydroxytryptamine7 Receptors: Evidence for In Situ G Protein-Coupled Receptor Homodimer Protomer Cross-Talk. Mol. Pharmacol. 2011, 79, 318–325. [Google Scholar] [CrossRef] [Green Version]
  15. Lacivita, E.; Perrone, R.; Margari, L.; Leopoldo, M. Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. J. Med. Chem. 2017, 60, 9114–9141. [Google Scholar] [CrossRef]
  16. Varghese, M.; Keshav, N.; Jacot-Descombes, S.; Warda, T.; Wicinski, B.; Dickstein, D.L.; Harony-Nicolas, H.; De Rubeis, S.; Drapeau, E.; Buxbaum, J.D.; et al. Autism spectrum disorder: Neuropathology and animal models. Acta Neuropathol. 2017, 134, 537–566. [Google Scholar] [CrossRef]
  17. Crawley, J.N. Translational animal models of autism and neurodevelopmental disorders. Dialogues Clin. Neurosci. 2012, 14, 293–305. [Google Scholar] [CrossRef]
  18. Sztainberg, Y.; Zoghbi, H.Y. Lessons learned from studying syndromic autism spectrum disorders. Nat. Neurosci. 2016, 19, 1408–1417. [Google Scholar] [CrossRef]
  19. Rubenstein, J.L.; Merzenich, M.M. Model of autism: Increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003, 2, 255–267. [Google Scholar] [CrossRef]
  20. Berg, J.M.; Geschwind, D.H. Autism genetics: Searching for specificity and convergence. Genome Biol. 2012, 13, 247–262. [Google Scholar] [CrossRef] [Green Version]
  21. The Network and Pathway Analysis Subgroup of the Psychiatric Genomics Consortium. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat. Neurosci. 2015, 18, 199–209. [Google Scholar] [CrossRef]
  22. Merrill, J.E. Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: Normal and pathological. Dev. Neurosci. 2004, 14, 1–10. [Google Scholar] [CrossRef]
  23. Hranilovic, D.; Bujas-Petkovic, Z.; Vragovic, R.; Vuk, T.; Hock, K.; Jernej, B. Hyperserotonemia in adults with autistic disorder. J. Autism Dev. Disord. 2007, 37, 1934–1940. [Google Scholar] [CrossRef]
  24. Veenstra-VanderWeele, J.; Muller, C.L.; Iwamoto, H.; Sauer, J.E.; Owens, W.A.; Shah, C.R.; Cohen, J.; Mannangatti, P.; Jessen, T.; Thompson, B.J.; et al. Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior. Proc. Natl. Acad. Sci. USA 2012, 109, 5469–5474. [Google Scholar] [CrossRef] [Green Version]
  25. Muller, C.L.; Anacker, A.M.; Veenstra-VanderWeele, J. The serotonin system in autism spectrum disorder: From biomarker to animal models. Neuroscience 2016, 321, 24–41. [Google Scholar] [CrossRef] [Green Version]
  26. Hadjikhani, N. Serotonin, pregnancy and increased autism prevalence: Is there a link? Med. Hypotheses 2010, 74, 880–883. [Google Scholar] [CrossRef]
  27. Yang, C.J.; Tan, H.-P.; Du, Y.-J. The developmental disruptions of serotonin signaling may involved in autism during early brain development. Neuroscience 2014, 267, 1–10. [Google Scholar] [CrossRef]
  28. Harrington, R.A.; Lee, L.-C.; Crum, R.M.; Zimmerman, A.W.; Hertz-Picciotto, I. Serotonin hypothesis of autism: Implications for selective serotonin reuptake inhibitor use during pregnancy. Autism Res. 2013, 6, 149–168. [Google Scholar] [CrossRef]
  29. Kepser, L.-J.; Homberg, J.R. The neurodevelopmental effects of serotonin: A behavioural perspective. Behav. Brain Res. 2015, 277, 3–13. [Google Scholar] [CrossRef]
  30. Croen, L.A.; Grether, J.K.; Yoshida, C.K.; Odouli, R.; Hendrick, V. Antidepressant Use During Pregnancy and Childhood Autism Spectrum Disorders. Arch. Gen. Psychiatry 2011, 68, 1104–1112. [Google Scholar] [CrossRef] [Green Version]
  31. Hviid, A.; Melbye, M.; Pasternak, B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N. Engl. J. Med. 2013, 369, 2406–2415. [Google Scholar] [CrossRef] [Green Version]
  32. Payet, J.M.; Burnie, E.; Sathananthan, N.J.; Russo, A.M.; Lawther, A.J.; Kent, S.; Lowry, C.A.; Hale, M.W. Exposure to acute and chronic fluoxetine has differential effects on sociability and activity of serotonergic neurons in the dorsal raphe nucleus of juvenile male BALB/c mice. Neuroscience 2018, 386, 1–15. [Google Scholar] [CrossRef] [PubMed]
  33. Rapport, M.M.; Green, A.A.; Page, I.H. Serum vasoconstrictor, serotonin; isolation and characterization. J. Biol. Chem. 1948, 176, 1243–1251. [Google Scholar] [CrossRef]
  34. Pithadia, A.B.; Jain, S.M. 5-Hydroxytryptamine Receptor Subtypes and their Modulators with Therapeutic Potentials. J. Clin. Med. Res. 2009, 1, 72–80. [Google Scholar] [CrossRef] [Green Version]
  35. Whitaker-Azmitia, P. Serotonin and brain development: Role in human developmental diseases. Brain Res. Bull. 2001, 56, 479–485. [Google Scholar] [CrossRef]
  36. Wirth, A.; Holst, K.; Ponimaskin, E. How serotonin receptors regulate morphogenic signalling in neurons. Prog. Neurobiol. 2017, 151, 35–56. [Google Scholar] [CrossRef]
  37. Lanfumey, L.; Hamon, M. 5-HT1 receptors. Curr. Drug Target CNS Neurol. Disord. 2004, 3, 1–10. [Google Scholar] [CrossRef]
  38. Khatri, N.; Simpson, K.L.; Lin, R.C.S.; Paul, I.A. Lasting neurobehavioral abnormalities in rats after neonatal activation of serotonin 1A and 1B receptors: Possible mechanisms for serotonin dysfunction in autistic spectrum disorders. Psychopharmacology 2014, 231, 1191–1200. [Google Scholar] [CrossRef]
  39. Hollander, E.; Novotny, S.; Allen, A.; Aronowitz, B.; Cartwright, C.; DeCaria, C. The relationship between repetitive behaviors and growth hormone response to sumatriptan challenge in adult autistic disorder. Neuropsychopharmacology 2000, 22, 163–167. [Google Scholar] [CrossRef]
  40. De Boer, S.F.; Newman-Tancredi, A. Anti-aggressive effects of the selective high-efficacy ‘biased’-5-HT1A receptor agonists F15599 and F13714 in male WTG rats. Psychopharmacology 2016, 233, 937–947. [Google Scholar] [CrossRef] [Green Version]
  41. Cosi, C.; Martel, J.-C.; Auclair, A.L.; Collo, G.; Cavalleri, L.; Heusler, P.; Leriche, L.; Gaudoux, F.; Sokoloff, P.; Moser, P.G.; et al. Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist. Eur. J. Pharmacol. 2021, 890, 173635–173648. [Google Scholar] [CrossRef] [PubMed]
  42. Dufour-Rainfray, D.; Vourc’h, P.; Le Guisquet, A.-M.; Garreau, L.; Ternant, D.; Bodard, S.; Jaumain, E.; Gulhan, Z.; Belzung, C.; Andres, C.R.; et al. Behavior and serotonergic disorders in rats exposed prenatally to valproate: A model for autism. Neurosci. Lett. 2010, 470, 55–59. [Google Scholar] [CrossRef] [PubMed]
  43. Achterberg, E.J.M.; Trezza, V.; Siviy, S.M.; Schrama, L.; Schoffelmeer, A.N.M.; Vanderschuren, L.J.M.J. Amphetamine and cocaine suppress social play behavior in rats through distinct mechanism. Psychopharmacology 2014, 231, 1503–1515. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Mogha, A.; Guariglia, S.R.; Debata, P.R.; Wen, G.Y.; Banerjee, P. Setotonin 1A receptor-mediated signaling through ERK and PKCα is essential for normal synaptogenesis in neonatal mouse hippocampus. Transl. Psychiatry 2012, 2, e66. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Lawson, S.K.; Gray, A.C.; Woehrle, N.S. Effects of oxytocin on serotonin 1B agonist-induced autism-like behavior in mice. Behav. Brain Res. 2016, 314, 52–64. [Google Scholar] [CrossRef] [PubMed]
  46. King, J.R.; Velasquez, J.C.; Torii, M.; Bonnin, A. Effect of maternal ±citalopram exposure on P11 expression and neurogenesis in the mouse fetal brain. ACS Chem. Neurosci. 2017, 8, 1019–1025. [Google Scholar] [CrossRef]
  47. Svenningsson, P.; Chergui, K.; Rachleff, I.; Flajolet, M.; Zhang, X.; Yacoubi, M.E.; Vaugeois, J.-M.; Nomikos, G.G.; Greengard, P. Alterations in 5-HT1B Receptor Function by p11 in Depression-Like States. Science 2006, 311, 77–80. [Google Scholar] [CrossRef] [Green Version]
  48. Larke, R.H.; Maninger, N.; Ragen, B.; Mendoza, S.P.; Bales, K.L. Serotonin 1A agonism decreases affiliative behavior in pair-bonded titi monkeys. Horm. Behav. 2016, 86, 71–77. [Google Scholar] [CrossRef] [Green Version]
  49. Wu, H.-F.; Chen, Y.-J.; Chu, M.-C.; Hsu, Y.-T.; Lu, T.-Y.; Chen, I.-T.; Chen, P.S.; Lin, H.-C. Deep brain stimulation modified autism-like deficits via the serotonin system in a valproic acid-induced rat model. Int. J. Mol. Sci. 2018, 19, 2840. [Google Scholar] [CrossRef] [Green Version]
  50. Witt, N.A.; Lee, B.; Ghent, K.; Zhang, W.Q.; Pehrson, A.L.; Sánchez, C.; Gould, G.G. Vortioxetine reduces marble burying but only transiently enhances social interaction preference in adult male BTBR T+Itpr3tt/J mice. ACS Chem. Neurosci. 2019, 10, 4319–4327. [Google Scholar] [CrossRef]
  51. Leysen, J.E. 5-HT2 Receptors. Curr. Drug Targets CNS Neurol. Disord. 2004, 3, 11–26. [Google Scholar] [CrossRef] [PubMed]
  52. Bockaert, J.; Claeysen, S.; Dumuis, A.; Marin, P. Classification and Signaling Characteristics of 5-HT Receptors. In Handbook of the Behavioural Neurobiology of Serotonin; Muller, C.P., Jacobs, B.L., Eds.; Elesevier: London, UK, 2010; pp. 103–122. [Google Scholar]
  53. Kowalewska, B.; Drozdz, W.; Kowalewski, L. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) in autism research: Literature review. Ir. J. Psychol. Med. 2021, 1–15. [Google Scholar] [CrossRef] [PubMed]
  54. Chugani, D.C.; Muzik, O.; Rothermel, R.; Behen, M.; Chakraborty, P.; Mangner, T.; da Silva, E.A.; Chugani, H.T. Altered Serotonin Synthesis in the Dentatothalamocortical Pathway in Autistic Boys. Ann. Neurol. 1997, 42, 666–669. [Google Scholar] [CrossRef]
  55. Chugani, D.C.; Muzik, O.; Behen, M.; Rothermel, R.; Janisse, J.J.; Lee, J.; Chugani, H.T. Developmental Changes in Brain Serotonin Synthesis Capacity in Autistic and Nonautistic Children. Ann. Neurol. 1999, 45, 287–295. [Google Scholar] [CrossRef]
  56. Goldberg, J.; Anderson, G.M.; Zwaigenbaum, L.; Hall, G.B.C.; Nahmias, C.; Thompson, A.; Szatmari, P. Cortical Serotonin Type-2 Receptor Density in Parents of Children with Autism Spectrum Disorders. J. Autism Dev. Disord. 2009, 39, 97–104. [Google Scholar] [CrossRef]
  57. Beversdorf, D.Q.; Nordgren, R.E.; Bonab, A.A.; Fischman, A.J.; Weise, S.B.; Dougherty, D.D.; Felopulos, G.J.; Zhou, F.C.; Bauman, M.L. 5-HT2 Receptor Distribution Shown by [18F] Setoperone PET in High-Functioning Autistic Adults. J. Neuropsychiatry Clin. Neurosci. 2012, 24, 191–197. [Google Scholar] [CrossRef]
  58. Gadow, K.D.; Smith, R.M.; Pinsonneault, J.K. Serotonin 2A Receptor Gene (HTR2A) Regulatory Variants: Possible Association with Severity of Depression Symptoms in Children with Autism Spectrum Disorder. Cogn. Behav. Neurol. 2014, 27, 107–116. [Google Scholar] [CrossRef]
  59. Smith, R.M.; Banks, W.; Hansen, E.; Sadee, W.; Herman, G.E. Family-Based Clinical Associations and Functional Characterization of the Serotonin 2A Receptor Gene (HTR2A) in Autism Spectrum Disorder. Autism Res. 2014, 7, 459–467. [Google Scholar] [CrossRef] [Green Version]
  60. Doyle, C.A.; McDougle, C.J. Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin. Neurosci. 2012, 14, 263–279. [Google Scholar] [CrossRef]
  61. Stigler, K.A.; Mullett, J.E.; Erickson, C.A.; Posey, D.J.; McDougle, C.J. Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology 2012, 223, 237–245. [Google Scholar] [CrossRef]
  62. Román, V.; Adham, N.; Foley, A.G.; Hanratty, L.; Farkas, B.; Lendvai, B.; Kiss, B. Cariprazine alleviates core behavioral deficits in the prenatal valproic acid exposure model of autism spectrum disorder. Psychopharmacology 2021, 238, 2381–2392. [Google Scholar] [CrossRef] [PubMed]
  63. Amodeo, D.A.; Jones, J.H.; Sweeney, J.A.; Ragozzino, M.E. Risperidone and the 5-HT2A Receptor Antagonist M100907 Improve Probabilistic Reversal Learning in BTBR T + tf/J Mice. Autism Res. 2014, 7, 555–567. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Amodeo, D.A.; Rivera, E.; Dunn, J.T.; Ragozzino, M.E. M100907 attenuates elevated grooming behavior in the BTBR mouse. Behav. Brain Res. 2016, 313, 67–70. [Google Scholar] [CrossRef] [PubMed]
  65. Amodeo, D.A.; Rivera, E.; Cook Jr, E.H.; Sweeney, J.A.; Ragozzino, M.E. 5HT2A receptor blockade in dorsomedial striatum reduces repetitive behaviors in BTBR mice. Genes Brain Behav. 2017, 16, 342–351. [Google Scholar] [CrossRef] [Green Version]
  66. Panzini, C.M.; Ehlinger, D.G.; Alchahin, A.M.; Guo, Y.; Commons, K.G. 16p11.2 deletion syndrome mice perseverate with active coping response to acute stress–rescue by blocking 5-HT2A receptors. J. Neurochem. 2017, 143, 708–721. [Google Scholar] [CrossRef]
  67. Baker, P.M.; Thompson, J.L.; Sweeney, J.A.; Ragozzino, M.E. Differential effects of 5-HT2A and 5-HT2C receptor blockade on strategy-switching. Behav. Brain Res. 2011, 219, 123–131. [Google Scholar] [CrossRef] [Green Version]
  68. Amodeo, D.A.; Hassan, O.; Klein, L.; Halberstadt, A.L. Acute serotonin 2A receptor activation impairs behavioral flexibility in mice. Behav. Brain Res. 2020, 395, 112861. [Google Scholar] [CrossRef]
  69. Price, A.E.; Sholler, D.J.; Stutz, S.J.; Anastasio, N.C.; Cunningham, K.A. Endogenous Serotonin 5-HT2A and 5-HT2C Receptors Associate in the Medial Prefrontal Cortex. ACS Chem. Neurosci. 2019, 10, 3241–3248. [Google Scholar] [CrossRef]
  70. Halberstadt, A.L.; van der Heijden, I.; Ruderman, M.A.; Risbrough, V.B.; Gingrich, J.A.; Geyer, M.A.; Powell, S.B. 5-HT2A and 5-HT2C Receptors Exert Opposing Effects on Locomotor Activity in Mice. Neuropsychopharmacology 2009, 34, 1958–1967. [Google Scholar] [CrossRef] [Green Version]
  71. Mollinedo-Gajate, I.; Song, C.; Sintes-Rodriguez, M.; Whelan, T.; Soula, A.; Selimbeyoglu, A.; Hurley, S.; Knöpfel, T. Psilocybin rescues sociability deficits in an animal model of autism. bioRxiv 2020. [Google Scholar] [CrossRef]
  72. Séjourné, J.; Llaneza, D.; Kuti, O.J.; Page, D.T. Social Behavioral Deficits Coincide with the Onset of Seizure Susceptibility in Mice Lacking Serotonin Receptor 2c. PLoS ONE 2015, 10, e0136494. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Monsma, F.J.; Shen, Y.; Ward, R.P.; Hamblin, M.W.; Sibley, D.R. Cloning and Expression of a Novel Serotonin Receptor with High Affinity for Tricyclic Psychotropic Drugs. Mol. Pharmacol. 1993, 43, 320–327. [Google Scholar] [PubMed]
  74. Ruat, M.; Traiffort, E.; Arrang, J.M.; Tardivellacombe, J.; Diaz, J.; Leurs, R.; Schwartz, J.C. A Novel Rat Serotonin (5-HT6) Receptor: Molecular Cloning, Localization and Stimulation of cAMP Accumulation. Biochem. Biophys. Res. Commun. 1993, 193, 268–276. [Google Scholar] [CrossRef] [PubMed]
  75. Kohen, R.; Metcalf, M.A.; Khan, N.; Druck, T.; Huebner, K.; Lachowicz, J.E.; Meltzer, H.Y.; Sibley, D.R.; Roth, B.L.; Hamblin, M.W. Cloning, Characterization, and Chromosomal Localization of a Human 5-HT6 Serotonin Receptor. J. Neurochem. 1996, 66, 47–56. [Google Scholar] [CrossRef] [PubMed]
  76. Gérard, C.; Martres, M.; Lefèvre, K.; Miquel, M.-C.; Vergé, D.; Lanfumey, L.; Doucet, E.; Hamon, M.; El Mestikawy, S. Immuno-Localization of Serotonin 5-HT6 Receptor-like Material in the Rat Central Nervous System. Brain Res. 1997, 746, 207–219. [Google Scholar] [CrossRef]
  77. Wesołowska, A. Potential Role of the 5-HT6 Receptor in Depression and Anxiety: An Overview of Preclinical Data. Pharmacol. Rep. 2010, 62, 564–577. [Google Scholar] [CrossRef]
  78. Yun, H.-M.; Rhim, H. The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp. Neurobiol. 2011, 20, 159–168. [Google Scholar] [CrossRef] [Green Version]
  79. Sebben, M.; Ansanay, H.; Bockaert, J.; Dumuis, A. 5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture. NeuroReport 1994, 5, 2553–2557. [Google Scholar] [CrossRef]
  80. Yun, H.-M.; Kim, S.; Kim, H.-J.; Kostenis, E.; Kim, J.I.; Seong, J.Y.; Baik, J.-H.; Rhim, H. The Novel Cellular Mechanism of Human 5-HT6 Receptor through an Interaction with Fyn. J. Biol. Chem. 2007, 282, 5496–5505. [Google Scholar] [CrossRef] [Green Version]
  81. Yun, H.-M.; Baik, J.-H.; Kang, I.; Jin, C.; Rhim, H. Physical Interaction of Jab1 with Human Serotonin 6 G-Protein-Coupled Receptor and Their Possible Roles in Cell Survival. J. Biol. Chem. 2010, 285, 10016–10029. [Google Scholar] [CrossRef] [Green Version]
  82. Kim, S.-H.; Kim, D.H.; Lee, K.H.; Im, S.-K.; Hur, E.-M.; Chung, K.C.; Rhim, H. Direct Interaction and Functional Coupling between Human 5-HT6 Receptor and the Light Chain 1 Subunit of the Microtubule-Associated Protein 1B (MAP1B-LC1). PLoS ONE 2014, 9, e91402. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  83. Meffre, J.; Chaumont-Dubel, S.; Mannoury la Cour, C.; Loiseau, F.; Watson, D.J.G.; Dekeyne, A.; Séveno, M.; Rivet, J.M.; Gaven, F.; Déléris, P.; et al. 5-HT6 Receptor Recruitment of mTOR as a Mechanism for Perturbed Cognition in Schizophrenia. EMBO Mol. Med. 2012, 4, 1043–1056. [Google Scholar] [CrossRef] [PubMed]
  84. Riemer, C.; Borroni, E.; Levet-Trafit, B.; Martin, J.R.; Poli, S.; Porter, R.H.P.; Bös, M. Influence of the 5-HT6 Receptor on Acetylcholine Release in the Cortex: Pharmacological Characterization of 4-(2-Bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a Potent and Selective 5-HT6 Receptor Antagonist. J. Med. Chem. 2003, 46, 1273–1276. [Google Scholar] [CrossRef] [PubMed]
  85. Tassone, A.; Madeo, G.; Schirinzi, T.; Vita, D.; Puglisi, F.; Ponterio, G.; Borsini, F.; Pisani, A.; Bonsi, P. Activation of 5-HT6 Receptors Inhibits Corticostriatal Glutamatergic Transmission. Neuropharmacology 2011, 61, 632–637. [Google Scholar] [CrossRef] [PubMed]
  86. Dawson, L.A.; Nguyen, H.Q.; Li, P. In vivo Effects of the 5-HT6 Antagonist SB-271046 on Striatal and Frontal Cortex Extracellular Concentrations of Noradrenaline, Dopamine, 5-HT, Glutamate and Aspartate. Br. J. Pharmacol. 2000, 130, 23–26. [Google Scholar] [CrossRef] [Green Version]
  87. Karila, D.; Freret, T.; Bouet, V.; Boulouard, M.; Dallemagne, P.; Rochais, C. Therapeutic Potential of 5-HT6 Receptor Agonists. J. Med. Chem. 2015, 58, 7901–7912. [Google Scholar] [CrossRef]
  88. Dayer, A.G.; Jacobshagen, M.; Chaumont-Dubel, S.; Marin, P. 5-HT6 Receptor: A New Player Controlling the Development of Neural Circuits. ACS Chem. Neurosci. 2015, 6, 951–960. [Google Scholar] [CrossRef]
  89. Mohler, E.G.; Baker, P.M.; Gannon, K.S.; Jones, S.S.; Shacham, S.; Sweeney, J.A.; Ragozzino, M.E. The Effects of PRX-07034, a Novel 5-HT6 Antagonist, on Cognitive Flexibility and Working Memory in Rats. Psychopharmacology 2012, 220, 687–696. [Google Scholar] [CrossRef] [Green Version]
  90. Berthoux, C.; Hamieh, A.M.; Rogliardo, A.; Doucet, E.L.; Coudert, D.; Ango, F.; Grychowska, K.; Chaumont-Dubel, S.; Zajdel, P.; Maldonado, R.; et al. Early 5-HT6 Receptor Blockade Prevents Symptom Onset in a Model of Adolescent Cannabis Abuse. EMBO Mol. Med. 2020, 12, e10605. [Google Scholar] [CrossRef]
  91. Foley, A.G.; Murphy, K.J.; Hirst, W.D.; Gallagher, H.C.; Hagan, J.J.; Upton, N.; Walsh, F.S.; Regan, C.M. The 5-HT6 Receptor Antagonist SB-271046 Reverses Scopolamine-Disrupted Consolidation of a Passive Avoidance Task and Ameliorates Spatial Task Deficits in Aged Rats. Neuropsychopharmacology 2004, 29, 93–100. [Google Scholar] [CrossRef]
  92. Hirst, W.D.; Stean, T.O.; Rogers, D.C.; Sunter, D.; Pugh, P.; Moss, S.F.; Bromidge, S.M.; Riley, G.; Smith, D.R.; Bartlett, S.; et al. SB-399885 Is a Potent, Selective 5-HT6 Receptor Antagonist with Cognitive Enhancing Properties in Aged Rat Water Maze and Novel Object Recognition Models. Eur. J. Pharmacol. 2006, 553, 109–119. [Google Scholar] [CrossRef] [PubMed]
  93. Amodeo, D.A.; Oliver, B.; Pahua, A.; Hitchcock, K.; Bykowski, A.; Tice, D.; Musleh, A.; Ryan, B.C. Serotonin 6 Receptor Blockade Reduces Repetitive Behavior in the BTBR Mouse Model of Autism Spectrum Disorder. Pharmacol. Biochem. Behav. 2021, 200, 173076. [Google Scholar] [CrossRef] [PubMed]
  94. Mitchell, E.S.; Hoplight, B.J.; Lear, S.P.; Neumaier, J.F. BGC20-761, a Novel Tryptamine Analog, Enhances Memory Consolidation and Reverses Scopolamine-Induced Memory Deficit in Social and Visuospatial Memory Tasks through a 5-HT6 Receptor-Mediated Mechanism. Neuropharmacology 2006, 50, 412–420. [Google Scholar] [CrossRef] [PubMed]
  95. Amodeo, D.A.; Peterson, S.; Pahua, A.; Posadas, R.; Hernandez, A.; Hefner, E.; Qi, D.; Vega, J. 5-HT6 Receptor Agonist EMD386088 Impairs Behavioral Flexibility and Working Memory. Behav. Brain Res. 2018, 349, 8–15. [Google Scholar] [CrossRef]
  96. Ciranna, L.; Catania, M.V. 5-HT7 receptors as modulators of neuronal excitability, synaptic transmission and plasticity: Physiological role and possible implications in autism spectrum disorders. Front. Cell. Neurosci. 2014, 8, 250. [Google Scholar] [CrossRef] [Green Version]
  97. Heidmann, D.E.; Metcalf, M.A.; Kohen, R.; Hamblin, M.W. Four 5-hydroxytryptamine7 (5-HT7) receptor isoforms in human and rat produced by alternative splicing: Species differences due to altered intron-exon organization. J. Neurochem. 1997, 68, 1372–1381. [Google Scholar] [CrossRef]
  98. Fukuhara, S.; Chikumi, H.; Gutkind, J.S. RGS-containing RhoGEFs: The missing link between transforming G proteins and Rho? Oncogene 2001, 20, 1661–1668. [Google Scholar] [CrossRef] [Green Version]
  99. Lassig, J.P.; Vachirasomtoon, K.; Hartzell, K.; Leventhal, M.; Courchesne, E.; Courchesne, R.; Lord, C.; Leventhal, B.L.; Cook, E.H., Jr. Physical mapping of the serotonin 5-HT(7) receptor gene (HTR7) to chromosome 10 and pseudogene (HTR7P) to chromosome 12, and testing of linkage disequilibrium between HTR7 and autistic disorder. Am. J. Med. Genet. 1999, 88, 472–475. [Google Scholar] [CrossRef]
  100. Khodaverdi, M.; Rahdar, M.; Davoudi, S.; Hajisoltani, R.; Tavassoli, Z.; Ghasemi, Z.; Amini, A.E.; Hosseinmardi, N.; Behzadi, G.; Janahmadi, M. 5-HT7 receptor activation rescues impaired synaptic plasticity in an autistic-like rat model induced by prenatal VPA exposure. Neurobiol. Learn. Mem. 2021, 183, 107462. [Google Scholar] [CrossRef]
  101. Canal, C.E.; Felsing, D.E.; Liu, Y.; Zhu, W.; Wood, J.T.; Perry, C.K.; Vemula, R.; Booth, R.G. An orally active phenylaminotetralin-chemotype serotonin 5-HT7 and 5-HT1A receptor partial agonist that corrects motor stereotypy in mouse models. ACS Chem. Neurosci. 2015, 6, 1259–1270. [Google Scholar] [CrossRef]
  102. Armstrong, J.L.; Casey, A.B.; Saraf, T.S.; Mukherjee, M.; Booth, R.G.; Canal, C.E. (S)-5-(2′-Fluorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-2-amine, a serotonin receptor modulator, possesses anticonvulsant, prosocial, and anxiolytic-like properties in an Fmr1 knockout mouse model of Fragile X syndrome and autism spectrum disorder. ACS Pharmacol. Transl. Sci. 2020, 3, 509–523. [Google Scholar] [PubMed] [Green Version]
  103. Perry, C.K.; Casey, A.B.; Felsing, D.E.; Vemula, R.; Zaka, M.; Herrington, N.B.; Cui, M.; Kellogg, G.E.; Canal, C.E.; Booth, R.G. Synthesis of novel 5-substituted-2-aminotetralin analogs: 5-HT1A and 5-HT7 G protein-coupled receptor affinity, 3D-QSAR and molecular modeling. Bioorg. Med. Chem. 2020, 28, 115262. [Google Scholar] [CrossRef] [PubMed]
  104. Kelemen, Á.A.; Satała, G.; Bojarski, A.J.; Keserű, G.M. Spiro[pyrrolidine-3,3′-oxindoles] as 5-HT7 receptor ligands. Bioorg. Med. Chem. Lett. 2018, 28, 2418–2421. [Google Scholar] [CrossRef] [PubMed]
  105. Lacivita, E.; Niso, M.; Mastromarino, M.; Silva, A.G.; Resch, C.; Zeug, A.; Loza, M.I.; Castro, M.; Ponimaskin, E.; Leopoldo, M. Knowledge-based design of long-chain arylpiperazine derivatives targeting multiple serotonin receptors as potential candidates for treatment of autism spectrum disorder. ACS Chem. Neurosci. 2021, 12, 1313–1327. [Google Scholar] [CrossRef]
  106. Gurevich, V.; Gurevich, E.V. GPCR signaling regulation: The role of GRKs and arrestins. Front. Pharmacol. 2019, 10, 125. [Google Scholar] [CrossRef] [Green Version]
  107. Kim, Y.; Kim, H.; Lee, J.; Lee, J.K.; Min, S.-J.; Seong, J.; Rhim, H.; Tae, J.; Lee, H.J.; Choo, H. Discovery of β-arrestin biased ligands of 5-HT7R. J. Med. Chem. 2018, 61, 7218–7233. [Google Scholar] [CrossRef]
  108. Brenchat, A.; Ejarque, M.; Zamanillo, D.; Vela, J.M.; Romero, L. Potentiation of morphine analgesia by adjuvant activation of 5-HT7 Receptors. J. Pharmacol. Sci. 2011, 116, 388–391. [Google Scholar] [CrossRef] [Green Version]
  109. Meneses, A.; Perez-Garcia, G.; Liy-Salmeron, G.; Flores-Galvez, D.; Castillo, C.; Castillo, E. The effects of the 5-HT(6) receptor agonist EMD and the 5-HT(7) receptor agonist AS19 on memory formation. Behav. Brain Res. 2008, 195, 112–119. [Google Scholar] [CrossRef]
  110. Bonaventure, P.; Dugovic, C.; Kramer, M.; De Boer, P.; Singh, J.; Wilson, S.; Bertelsen, K.; Di, J.; Shelton, J.; Aluisio, L.; et al. Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder. J. Pharmacol. Exp. Ther. 2012, 342, 429–440. [Google Scholar] [CrossRef] [Green Version]
  111. Lee, J.; Kwag, R.; Lee, S.; Kim, D.; Woo, J.; Cho, Y.; Kim, H.J.; Kim, J.; Jeon, B.; Choo, H. Discovery of G protein-biased ligands against 5-HT7R. J. Med. Chem. 2021, 64, 7453–7467. [Google Scholar] [CrossRef]
  112. Kwag, R.; Lee, J.; Kim, D.; Lee, H.; Yeom, M.; Woo, J.; Cho, Y.; Kim, H.J.; Kim, J.; Keum, G.; et al. Discovery of G protein-biased antagonists against 5-HT7R. J. Med. Chem. 2021, 64, 13766–13779. [Google Scholar] [CrossRef] [PubMed]
  113. Lee, J.; Avramets, D.; Jeon, B.; Choo, H. Modulation of Serotonin Receptors in Neurodevelopmental Disorders: Focus on 5-HT7 Receptor. Molecules 2021, 26, 3348. [Google Scholar] [CrossRef] [PubMed]
  114. Gaddum, J.H.; Picarelli, Z.P. Two kinds of tryptamine receptor. Br. J. Pharmacol. 1957, 12, 134–139. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  115. Barnes, N.M.; Ahern, G.P.; Becamel, C.; Bockaert, J.; Camilleri, M.; Chaumont-Dubel, S.; Claeysen, S.; Cunningham, K.A.; Fone, K.C.; Gershon, M.; et al. International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacol. Rev. 2021, 73, 310–520. [Google Scholar]
Table
Table 3. 5-HT6R-targeted pharmacological agents which have potential effects on ASD treatment.
Table 3. 5-HT6R-targeted pharmacological agents which have potential effects on ASD treatment.
NamesStructuresTargetsEffects
PRX-07034 [89] Ijms 23 06515 i0225-HT6R antagonistEnhancing working memory and cognitive flexibility
SB-258585 [90] Ijms 23 06515 i0235-HT6R antagonistPrevention of cognitive symptom onset
SB-271046 [91] Ijms 23 06515 i0245-HT6R antagonistReversing the amnesia produced by scopolamine administration; amelioration of spatial task deficits
SB-399885 [92] Ijms 23 06515 i0255-HT6R antagonistEnhancing cognitive function
BGC20-761 [93,94] Ijms 23 06515 i0265-HT6R antagonistReduced repetitive behavior; enhancing memory consolidation, reversing scopolamine-induced memory deficit
EMD386088 [95] Ijms 23 06515 i0275-HT6R agonistImpairments of behavioral flexibility and working memory
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lee, A.; Choo, H.; Jeon, B. Serotonin Receptors as Therapeutic Targets for Autism Spectrum Disorder Treatment. Int. J. Mol. Sci. 2022, 23, 6515. https://doi.org/10.3390/ijms23126515

AMA Style

Lee A, Choo H, Jeon B. Serotonin Receptors as Therapeutic Targets for Autism Spectrum Disorder Treatment. International Journal of Molecular Sciences. 2022; 23(12):6515. https://doi.org/10.3390/ijms23126515

Chicago/Turabian Style

Lee, Ansoo, Hyunah Choo, and Byungsun Jeon. 2022. "Serotonin Receptors as Therapeutic Targets for Autism Spectrum Disorder Treatment" International Journal of Molecular Sciences 23, no. 12: 6515. https://doi.org/10.3390/ijms23126515

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop